Harpoon Therapeutics Presents Updated Interim Results at ASH

Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma

Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , American , Roberth Uhl , , Exchange Commission , American Society Of Hematology , Harpoon Therapeutics Inc , Nasdaq , Harpoon Therapeutics , American Society , Annual Meeting , Activating Construct , Conference Call , Fast Track , Private Securities Litigation Reform Act , Harpoon Therapeutic ,